Comparative Pharmacology
Head-to-head clinical analysis: TRIPROLIDINE AND PSEUDOEPHEDRINE versus X TROZINE L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIPROLIDINE AND PSEUDOEPHEDRINE versus X TROZINE L A.
TRIPROLIDINE AND PSEUDOEPHEDRINE vs X-TROZINE L.A.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triprolidine is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing histamine-mediated allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and decreased nasal congestion.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
1 tablet (2.5 mg triprolidine/60 mg pseudoephedrine) orally every 4-6 hours; max 4 tablets/24 hours.
250 mg orally once daily. May be increased to 500 mg once daily if needed.
None Documented
None Documented
Triprolidine: 2-4 hours (parent compound). Pseudoephedrine: 4-8 hours, prolonged in alkaline urine (up to 16-24 hours).
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Triprolidine: renal, 70% unchanged and metabolites. Pseudoephedrine: renal, 90% unchanged.
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Category A/B
Category C
Antihistamine
Antihistamine